• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AnaptysBio Inc. (Amendment)

    2/13/24 4:58:53 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    SC 13G/A 1 tv0287-anaptysbioinc.htm SCHEDULE 13G/A anaptysbioinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  AnaptysBio Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  032724106

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  032724106

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    29,018

    7.  SOLE DISPOSITIVE POWER

    1,334,532

    8.  SHARED DISPOSITIVE POWER

    45,583

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,380,115

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.19%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    AnaptysBio Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    10770 Wateridge Circle, Suite 210
    San Diego, CA 92121-5801

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    032724106

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ANAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    1/7/2026$70.00Buy
    UBS
    10/13/2025$78.00Overweight
    Barclays
    6/4/2025$38.00Neutral → Buy
    H.C. Wainwright
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $ANAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

    Inclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. ("First Tracks Bio"), and EcoR1 Capital (the "Selling Stockholder") have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses. In the transaction, First Tracks Bio is selling an aggregate of 5,791,478 shares of First Tracks Bio's common stock (the "Primary Sha

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

    Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio common stock ownedFirst Tracks Bio initial cash balance of $180 million, inclusive of $80 million from private placement SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks Bio"). The new company is expected to begin "regular-way" trading on the Nasdaq Stock Market LLC ("Nasdaq") on April 20, 2026, under the

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

    Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investmentsSusannah Gray, former CFO of Royalty Pharma, appointed to Anaptys' Board of Directors SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding comm

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gray Susannah

    3 - ANAPTYSBIO, INC (0001370053) (Issuer)

    4/3/26 4:00:54 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Schmid John P.

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    4/1/26 9:28:11 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Anaptysbio, Inc

    3 - ANAPTYSBIO, INC (0001370053) (Reporting)

    4/1/26 4:31:39 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/2/25 6:17:02 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    8/16/24 12:04:31 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on AnaptysBio with a new price target

    UBS resumed coverage of AnaptysBio with a rating of Buy and set a new price target of $70.00

    1/7/26 8:39:16 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on AnaptysBio with a new price target

    Barclays initiated coverage of AnaptysBio with a rating of Overweight and set a new price target of $78.00

    10/13/25 8:51:16 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00

    6/4/25 7:31:04 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    SEC Filings

    View All

    AnaptysBio Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ANAPTYSBIO, INC (0001370053) (Filer)

    3/27/26 9:19:37 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.

    SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    3/26/26 3:43:33 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by AnaptysBio Inc.

    10-K - ANAPTYSBIO, INC (0001370053) (Filer)

    3/3/26 4:23:21 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 4:00:05 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 9:24:47 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

    SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

    8/16/24 12:07:11 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Leadership Updates

    Live Leadership Updates

    View All

    Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

    Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investmentsSusannah Gray, former CFO of Royalty Pharma, appointed to Anaptys' Board of Directors SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding comm

    3/27/26 9:00:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    Actym Therapeutics Appoints Thomas Smart as CEO

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Financials

    Live finance-specific insights

    View All

    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

    Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29

    9/29/25 4:05:49 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

    Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b

    5/11/23 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care